Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment

AIM: The aim of the present study was to characterize the pharmacokinetics of the oral proteasome inhibitor, ixazomib, in patients with solid tumours and moderate or severe hepatic impairment, to provide posology recommendations. METHODS: Eligible adults with advanced malignancies for which no furth...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Neeraj, Hanley, Michael J., Venkatakrishnan, Karthik, Perez, Raymond, Norris, Robin E., Nemunaitis, John, Yang, Huyuan, Qian, Mark G., Falchook, Gerald, Labotka, Richard, Fu, Siqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Pharmacokinetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5089614/
https://www.ncbi.nlm.nih.gov/pubmed/27121262
http://dx.doi.org/10.1111/bcp.12991

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5089614/
https://www.ncbi.nlm.nih.gov/pubmed/27121262
http://dx.doi.org/10.1111/bcp.12991

Ejemplares similares